Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTDS vs Standard Treatment in Elderly OA
NCT00324038Phase 4Completed
- Sponsor
- Napp Pharmaceuticals
- Start
- Mar 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of buprenorphine in osteoarthritis (OA) (2 arms), sponsored by Napp Pharmaceuticals. Primary endpoint: Average Daily Pain Scores (BS11) at 12 weeks. Started Mar 2006; status: completed.
02
Drugs
buprenorphine
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00324038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324038.